Chrysos Corporation's PhotonAssay adoption accelerates despite gold price swings

Chrysos Corporation Ltd (ASX: C79) has spent the past year proving out a technology substitution thesis: that its PhotonAssay platform, an X-ray-based alternative to traditional fire assay for testing gold and other metals, is steadily displacing legacy assay methods across the global mining industry. Ryder Capital laid out the foundational case in September 2025, noting the surge in gold prices had triggered a global increase in exploration drilling that stretched traditional assay turnaround times from weeks to, in some cases, months, creating structural demand for PhotonAssay's faster alternative.

Strong financial performance, then a gold price wobble

Yarra Capital Management tracked the company's financial acceleration closely through the second half of 2025 and into 2026, reporting FY25 revenue growth of 46% to AU$66.1 million alongside 80% EBITDA growth, before flagging even stronger 1H26 numbers in February 2026: revenue up 49% year-on-year and EBITDA up 152%, with the fund's positive view underpinned by the company having achieved only 5% global market penetration in a market where it is the clear leader. That momentum did not translate directly into share price strength, however; Ausbil Investment Management noted the stock fell 18.2% in May 2026 on concerns about near-term deployment timing for several units awaiting final site installation, even as adoption metrics, including 19 new leases signed year-to-date, were the fastest in years.

The lease signing cadence accelerates sharply

The clearest signal of accelerating adoption came in June 2026. Hyperion Asset Management reported that Chrysos had signed a further four PhotonAssay lease agreements, taking total lease agreements signed financial year-to-date to 23, including an additional unit for ALS in Saudi Arabia and an expanding global partnership with SGS. The fund noted this compared with just nine new lease agreements signed over the entirety of FY25, a sales cadence acceleration it attributed to increased industry activity from higher gold prices. Coinciding with the update, Chrysos refinanced its corporate facilities with a new three-year A$200 million syndicated facility to fund future deployments.

A capex-driven pullback tests investor patience

Not every reaction to the growth has been positive. ECP Asset Management trimmed its holding in March 2026 after a period of significant share price appreciation, noting the market took a more cautious approach toward the company's capital expenditure profile even as it remained on track to hit the upper end of FY26 guidance. Ryder Capital, by May 2026, described Chrysos as trading significantly below its assessment of intrinsic value after a soft month, while NorthStar Impact Funds framed the same pullback as reflecting broader gold price weakness rather than any deterioration in the underlying, genuinely disruptive photon-assay platform.

What managers are watching next

With PhotonAssay adoption still at an early stage of penetrating a global market of gold, silver and copper assay demand, and a refinanced $200 million facility now in place to fund further unit rollout, the catalysts fund managers are watching most closely are the pace of new lease signings relative to the accelerating FY26 run-rate, the timing of site installations for already-contracted units, and whether the gold price stabilises enough to remove the share price volatility that has periodically decoupled from the company's underlying operating momentum.